Aller au contenu
Santé cardiovasculaireRevue des preuves4 min read

Lowering blood pressure cuts heart events with or without diabetes; absolute benefit is similar

Collectif éditorial MoveVitals · Study published · Reading updated

Original paper:Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis. · The lancet. Diabetes & endocrinology · 2022 · Article original ↗

À retenir

Across 51 randomised trials with 358,533 participants, each 5 mm Hg lower systolic blood pressure reduced major cardiovascular events (HR 0.94, 95% CI 0.91-0.98 with type 2 diabetes; HR 0.89, 0.87-0.92 without). The relative effect was weaker with diabetes, but absolute reductions were similar, and the trials were published between 1981 and 2014.

Study design

Revue des preuves

Reading basis

Published abstract

Reading focus

Design & applicability

Cette explication éditoriale existe en anglais, chinois simplifié et chinois traditionnel. Cette interface affiche la lecture en anglais.

Question de recherche

It has been debated whether people with type 2 diabetes should have a different threshold for starting blood pressure treatment than people without it. The authors pooled individual participant data from major trials to compare the effect of lowering systolic blood pressure on major cardiovascular events by diabetes status, baseline blood pressure and drug class.

Population et méthode

One-stage individual participant-level data meta-analysis of randomised trials in the Blood Pressure Lowering Treatment Trialists' Collaboration dataset (PROSPERO CRD42018099283). Eligible trials compared blood pressure-lowering drugs with placebo or other classes, or intensive with standard strategies, had baseline diabetes status and at least 1000 person-years of follow-up per group; trials limited to heart failure, short-term therapy or acute settings were excluded. The primary outcome was a first major cardiovascular event (stroke or cerebrovascular disease, ischaemic heart disease, or heart failure causing death or hospitalisation), expressed per 5 mm Hg reduction in systolic pressure. Cox models stratified by trial gave hazard ratios by diabetes status and baseline systolic pressure; Poisson regression estimated absolute risk reductions; a network meta-analysis compared five drug classes.

Résultats

The authors’ reported results. Read each estimate with its population and uncertainty.

  1. 1
    The analysis covered 51 trials published between 1981 and 2014 with 358,533 participants (58% men), of whom 103,325 (29%) had type 2 diabetes at baseline. Median follow-up was 4.2 years (IQR 3.0-5.0).
  2. 2
    A 5 mm Hg reduction in systolic blood pressure lowered the risk of major cardiovascular events in both groups, with a weaker relative effect in type 2 diabetes (HR 0.94, 95% CI 0.91-0.98) than without (HR 0.89, 95% CI 0.87-0.92; p for interaction = 0.0013).
  3. 3
    Absolute risk reductions did not differ substantially between the groups, because people with diabetes had a higher absolute cardiovascular risk.
  4. 4
    There was no reliable evidence that treatment effects varied by baseline systolic pressure in either group, and no evidence that relative effects differed by diabetes status for any of the five drug classes.

Limites et incertitude

  1. 1
    The trials ran from 1981 to 2014, so background care for diabetes and cardiovascular risk differs from today.
  2. 2
    Median follow-up of 4.2 years may not capture longer-term benefits or harms, and the abstract does not report adverse effects such as low blood pressure.
  3. 3
    Estimates are per 5 mm Hg reduction in systolic pressure, a modelling convention that assumes similar effects across the trials' achieved reductions.
  4. 4
    This reading is based on the abstract only.

Mise en perspective

The authors conclude that people with and without type 2 diabetes got similar absolute benefit from lowering blood pressure, so they argue against different thresholds, intensities or drug classes by diabetes status. These are population averages from past trials, and your own target and treatment should be decided with your clinician.

Vos données

A validated upper-arm cuff is the right tool: measure at the same time of day, seated and rested, and record repeated readings over weeks. Wrist watches that estimate blood pressure are not a substitute for these trials' clinic measurements. Bring your home log to appointments.

Comprendre ce type de preuve

Check which designs were included, how searches and bias assessment were conducted, and the last search date. Publication date alone does not make the underlying evidence current.

Résumé structuré des auteurs English

Le résumé original en anglais est reproduit avec attribution sous la licence ouverte indiquée. Il s’agit d’une source, pas d’une interprétation MoveVitals. L’analyse préparée figure ci-dessus ; vérifiez les conclusions importantes dans la source.

Background

Controversy exists as to whether the threshold for blood pressure-lowering treatment should differ between people with and without type 2 diabetes. We aimed to investigate the effects of blood pressure-lowering treatment on the risk of major cardiovascular events by type 2 diabetes status, as well as by baseline levels of systolic blood pressure.

Methods

We conducted a one-stage individual participant-level data meta-analysis of major randomised controlled trials using the Blood Pressure Lowering Treatment Trialists' Collaboration dataset. Trials with information on type 2 diabetes status at baseline were eligible if they compared blood pressure-lowering medications versus placebo or other classes of blood pressure-lowering medications, or an intensive versus a standard blood pressure-lowering strategy, and reported at least 1000 persons-years of follow-up in each group. Trials exclusively on participants with heart failure or with short-term therapies and acute myocardial infarction or other acute settings were excluded. We expressed treatment effect per 5 mm Hg reduction in systolic blood pressure on the risk of developing a major cardiovascular event as the primary outcome, defined as the first occurrence of fatal or non-fatal stroke or cerebrovascular disease, fatal or non-fatal ischaemic heart disease, or heart failure causing death or requiring hospitalisation. Cox proportional hazard models, stratified by trial, were used to estimate hazard ratios (HRs) separately by type 2 diabetes status at baseline, with further stratification by baseline categories of systolic blood pressure (in 10 mm Hg increments from <120 mm Hg to ≥170 mm Hg). To estimate absolute risk reductions, we used a Poisson regression model over the follow-up duration. The effect of each of the five major blood pressure-lowering drug classes, including angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, β blockers, calcium channel blockers, and thiazide diuretics, was estimated using a network meta-analysis framework. This study is registered with PROSPERO, CRD42018099283.

Findings

We included data from 51 randomised clinical trials published between 1981 and 2014 involving 358 533 participants (58% men), among whom 103 325 (29%) had known type 2 diabetes at baseline. The baseline mean systolic/diastolic blood pressure of those with and without type 2 diabetes was 149/84 mm Hg (SD 19/11) and 153/88 mm Hg (SD 21/12), respectively. Over 4·2 years median follow-up (IQR 3·0-5·0), a 5 mm Hg reduction in systolic blood pressure decreased the risk of major cardiovascular events in both groups, but with a weaker relative treatment effect in participants with type 2 diabetes (HR 0·94 [95% CI 0·91-0·98]) compared with those without type 2 diabetes (0·89 [0·87-0·92]; p_(interaction)=0·0013). However, absolute risk reductions did not differ substantially between people with and without type 2 diabetes because of the higher absolute cardiovascular risk among participants with type 2 diabetes. We found no reliable evidence for heterogeneity of treatment effects by baseline systolic blood pressure in either group. In keeping with the primary findings, analysis using stratified network meta-analysis showed no evidence that relative treatment effects differed substantially between participants with type 2 diabetes and those without for any of the drug classes investigated.

Interpretation

Although the relative beneficial effects of blood pressure reduction on major cardiovascular events were weaker in participants with type 2 diabetes than in those without, absolute effects were similar. The difference in relative risk reduction was not related to the baseline blood pressure or allocation to different drug classes. Therefore, the adoption of differential blood pressure thresholds, intensities of blood pressure lowering, or drug classes used in people with and without type 2 diabetes is not warranted.

Funding

British Heart Foundation, UK National Institute for Health Research, and Oxford Martin School.

Sources et attribution

Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis.

Nazarzadeh M, Bidel Z, Canoy D, Copland E, Bennett DA, Dehghan A, Davey Smith G, Holman RR, Woodward M, Gupta A, Adler AI, Wamil M, Sattar N, Cushman WC, McManus RJ, Teo K, Davis BR, Chalmers J, Pepine CJ, Rahimi K, Blood Pressure Lowering Treatment Trialists' Collaboration.

The lancet. Diabetes & endocrinology · 2022-07-22

DOI: 10.1016/s2213-8587(22)00172-3 ↗PubMed · 35878651 ↗Europe PMC · Licence indiquée: cc by ↗

Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.

Interprétation éditoriale MoveVitals · contenu éducatif · aucune évaluation clinique individuelle enregistrée

Sources vérifiées 2026-11-01

Guides pratiques

À lire ensemble

·Méta-analyse observationnelle

Disrupted daily rest-activity rhythm is linked to higher mortality in 109,365 people

Across seven observational studies with 109,365 participants, a weaker day-night activity contrast (lower relative amplitude) was associated with higher cardiovascular mortality (hazard ratio [HR] 1.50, 95% CI 1.13 to 1.98) and all-cause mortality (HR 1.46, 95% CI 1.27 to 1.68). The evidence base is small and observational, so it cannot show that improving the rhythm lowers risk, and illness may itself disturb the rhythm.

Journal of the American Heart Association

Explications approfondiesLire l’étude →
·Méta-analyse d’essais

Five exercise types lowered resting blood pressure, isometric training the most

Pooling 270 randomised trials with 15,827 participants, aerobic, resistance, combined, interval and isometric training all lowered resting blood pressure compared with non-intervention controls (P<0.001 for each), with the largest fall for isometric training: 8.24 mm Hg systolic and 4.00 mm Hg diastolic. The ranking between modes is partly indirect and the trials differ, so it is not a personal prescription.

British Journal of Sports Medicine

Explications approfondiesLire l’étude →
·Essai randomisé

A salt substitute lowered stroke, major cardiovascular events and death in rural China

In 20,995 people in 600 rural Chinese villages who had a history of stroke or were 60 or older with high blood pressure, a salt substitute (75% sodium chloride, 25% potassium chloride) lowered the stroke rate versus regular salt over a mean 4.74 years: 29.14 versus 33.65 events per 1000 person-years (rate ratio 0.86, 95% CI 0.77 to 0.96; P = 0.006). Death was also lower (rate ratio 0.88) and serious hyperkalemia events were not significantly higher, but the trial was open-label and set in rural China.

The New England Journal of Medicine

Explications approfondiesLire l’étude →
·Validation : étude/revue

Apple Watch irregular-pulse alerts were rare; 34% of those tested had atrial fibrillation

Among 419,297 Apple Watch users with no known atrial fibrillation (AF), 0.52% received an irregular-pulse alert, and 34% of the 450 who returned a usable ECG patch had AF (97.5% CI 29 to 39). Alerts that coincided with patch recording matched AF with a positive predictive value of 0.84 (95% CI 0.76 to 0.92), but only 20.8% of alerted people returned a patch and nobody without an alert was monitored, so a quiet watch does not rule AF out.

The New England Journal of Medicine

Explications approfondiesLire l’étude →
Santé cardiovasculaire →